|
|
||||||||
Original Research Communications |
1 From the Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston.
2 Any opinions, findings, conclusions, or recommendations expressed in this publication are those of the authors and do not necessarily reflect the views of the US Department of Agriculture.
3 Supported in part by the US Department of Agriculture under agreement 58-1950-9-001 and by a grant from Nestlé Inc.
4 Address reprint requests to SN Meydani, Nutritional Immunology Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, 711 Washington Street, Boston, MA 02111. E-mail: S_Meydani_IM{at}HNRC.Tufts.edu.
| ABSTRACT |
|---|
|
|
|---|
-linolenic (18:3n-6) and
-linolenic (18:3n-3) acids, has been shown to modulate membrane lipid composition and eicosanoid production. Objective: Our objectives were to 1) test whether dietary supplementation with BCSO can improve the immune response of healthy elderly subjects, and 2) determine whether the altered immune response is mediated by a change in the factors closely associated with T cell activation.
Design: A randomized, double-blind, placebo-controlled (soybean oil) study was conducted to examine the effect of 2 mo of BCSO supplementation on the immune response of 40 healthy subjects aged
65 y. In vivo immune function was determined by delayed-type hypersensitivity skin response. Peripheral blood mononuclear cells (PBMCs) were tested for in vitro immune response.
Results: In subjects supplemented with BCSO, the total diameter of induration at 24 h and individual responses to tetanus toxoid and Trichophyton mentagrophytes were significantly higher than their baseline values. The change in response to tetanus toxoid was significantly different from that of the placebo group. The BCSO group showed a significant increase in proliferative response of PBMCs to the T cell mitogen phytohemagglutinin that was not significantly different from that observed in the placebo group. BCSO had no effect on concanavalin Ainduced mitogenic response, interleukin 2 and -1ß production, and PBMC membrane fluidity. Prostaglandin E2 production was significantly reduced in the BCSO-supplemented group, and this change was significantly different from that of the placebo group.
Conclusion: BCSO has a moderate immune-enhancing effect attributable to its ability to reduce prostaglandin E2 production.
Key Words:
-Linolenic acid fatty acids black currant seed oil immune function aging prostaglandins eicosanoids
| INTRODUCTION |
|---|
|
|
|---|
Black currant seed oil (BCSO) is rich in both the n-6 PUFA
-linolenic acid (18:3n-6) and the n-3 PUFA
-linolenic acid (18:3n-3). In addition, it contains a small amount of stearidonic acid (18:4n-3). The composition of BCSO reflects the recommended optimal dietary intake of n-3 and n-6 fatty acids, ie, it has a ratio of n-3 to n-6 fatty acids of 1 to 4 or 5 (2). The effect of
-linolenic acid on immune response is not well documented. We showed previously that long-term dietary supplementation with
-linolenic acid has no effect on the cell-mediated immune function of nonhuman primates (3). Stearidonic acid has been reported to inhibit platelet aggregation and arachidonate 5-lipoxygenase activity (4), suggesting that it might have antithrombotic and antiinflammatory properties.
Several reports have indicated that
-linolenic acid has antiinflammatory and immunomodulating effects.
-Linolenic acid is present in small amounts in the oils commonly used in Western diets but is found in high concentrations in certain other plant oils such as borage oil (23%), BCSO (18%), and evening primrose oil (9%). It can also be generated in the body through the desaturation of linoleic acid (18:2n-6) by the action of the rate-limiting enzyme linoleoyl-CoA desaturase (
6 desaturase). The activity of linoleoyl-CoA desaturase is under hormonal and metabolic regulation and can be influenced by certain diseases (5). For example, linoleoyl-CoA desaturase has been shown to be stimulated by insulin and inhibited by epinephrine, cortisol, thyroxine, glucagon, and saturated fat (57). In addition, linoleoyl-CoA desaturase activity decreases with age (8). Lower
-linolenic concentrations have also been reported in patients with inflammatory diseases (911), whereas administration of
-linolenic has been shown to elevate tissue
-linolenic concentrations and improve some clinical outcome measures of rheumatoid arthritis (12) or experimentally induced arthritis in an animal model (13).
The investigation of botanical oils rich in
-linolenic has thus far focused mostly on their antiinflammatory potential, but no comprehensive study has evaluated their effect on cell-mediated immune function in humans. Therefore, in this study we investigated the effect of BCSO (1519%
-linolenic acid) on the immune response of healthy elderly subjects.
| SUBJECTS AND METHODS |
|---|
|
|
|---|
65 y of age of both sexes. The study protocol was approved by the Tufts University/New England Medical Center Human Investigation Review Committee.
In this double-blind, placebo-controlled protocol, subjects were randomly assigned to either the placebo (20 subjects) or the BCSO (20 subjects) group. Each group received 6 placebo or BCSO capsules per day. Each BCSO capsule contained 750 mg BCSO (15%
-linolenic acid), and each placebo capsule contained 750 mg soybean oil. Both oils contained adequate amounts of
-tocopherol, calculated by using the formula that estimates minimum requirements of vitamin E for fatty acids with varying degrees of unsaturation (14). The fatty acid composition and vitamin E contents of the soybean oil and BCSO capsules are shown in Table 1
. The total amount of fat provided by either supplement was 4.5 g or 1.46% of total daily energy intake (calculated from 3-d dietary records).
|
Plasma fatty acids
Plasma samples (50 µL) were extracted with chloroform-methanol, as described previously (15), to isolate the total lipid fraction. The trichloromethane layer was collected and evaporated under nitrogen at 40°C, and the lipid residue was dissolved in 0.25 mL benzene. The fatty acids were methylated by addition of 0.75 mL of a freshly prepared solution of 10% acetyl chloride in methanol (16), followed by heating at 70°C for 2 h. After cooling, 1.2 mL of 7% aqueous NaCl was added, followed by 2 mL hexane to extract the fatty acid methyl esters.
The hexane extract was concentrated to a 100-µL volume and purified by HPLC (model 1100; Hewlett-Packard, Avondale, PA) to eliminate free cholesterol from the extract. We used an amino column (250 x 4.6 mm, particle size 5 µm; Alltech, Deerfield, IL). The initial mobile phase was 98% hexane, 2% isopropanol, with a flow rate of 1.5 mL/min and an 8-min linear ramp to 10% isopropanol. The HPLC retention times for fatty acid methyl esters and for cholesterol were determined by HPLC analysis of authentic standards at 220 nm. Removal of cholesterol avoids artifacts and column damage that can results from injection of cholesterol onto the gas chromatograph.
Purified fatty acid methyl esters were transferred to 50 µL dichloromethane and 1 µL was analyzed by gas chromatography (model 5890; Hewlett-Packard) on an apparatus equipped with a flame ionization detector. Separation was accomplished by using a 30-m AT-Wax capillary column with a 0.32-mm internal diameter and 0.5-µm film thickness (Alltech). The initial column temperature of 100°C was increased by 10°C/min to 250°C. Injections were made without split, and the split flow was turned on after 30 s. Fatty acid methyl esters in the samples were identified with authentic standards (Sigma Chemical Co, St Louis). Chromatograms were recorded digitally and peak areas were determined with GRAMS-386 software (Galactic Industries, Salem, NH).
Isolation of mononuclear cells
Forty milliliters of blood was collected into heparin-containing Vacutainers (Becton Dickinson, Rutherford, NJ) after subjects had fasted for 14 h. Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood by using Ficoll-Paque (Pharmacia Biotech, Piscataway, NJ) density-gradient centrifugation. The buffy layer was collected and washed twice in RPMI 1640 medium (Sigma) supplemented with 100000 U penicillin/L, 100 mg streptomycin/L (Gibco Laboratories, Grand Island, NY), 2 mmol L-glutamine/L (Gibco), and 25 mmol HEPES/L (Sigma) (complete RPMI). Cells were counted under a light microscope. Cell viability was assessed by using trypan blue exclusion. Cells were suspended in complete RPMI containing heat-inactivated autologous plasma at appropriate concentrations for different cultures.
Lymphocyte proliferation
Lymphocyte proliferation was measured by [3H]thymidine incorporation after stimulation with T cell mitogens. PBMCs at 1 x 105 cells/well (0.2 mL) in complete RPMI with 5% autologous plasma were cultured in 96-well flat-bottom plates (Becton Dickinson Labware, Lincoln Park, NJ) in the presence or absence of the T cell mitogens concanavalin A (ConA; Sigma) or phytohemagglutinin (PHA; Difco Laboratories, Detroit) at 0.5, 5, and 50 mg/L for 72 h at 37°C in an atmosphere of 5% CO2 and 95% humidity. Cultures were pulsed with 18.5 µBq of [3H]thymidine (specific radioactivity of 247.9 GBq/mol; DuPont NEN Products, Boston) during the final 4 h of incubation. Cells were harvested onto glass microtiter filter paper by using a cell harvester (PHD, Cambridge, MA) and counted in a liquid scintillation counter (Beckman Instruments, Palo Alto, CA). The counter had an efficiency of 50% for tritium. The results are reported as corrected counts per minute (ccpm: cpm of mitogen-stimulated cultures minus the cpm of cultures without mitogen).
Interleukin 1ß production
PBMCs, at 2.5 x 106 cells/well (1 mL) in complete RPMI with 1% autologous plasma, were cultured in 24-well flat-bottom plates (Becton Dickinson Labware) in the presence or absence of 1 µg lipopolysaccharide (LPS)/L (Escherichia coli 0111:B4; Sigma) or heat-killed Staphylococcus epidermis at 20 organisms per PBMC for 24 h. The plates were stored at -20°C. To measure total interleukin 1ß (IL-1ß; cell-associated and secreted), the samples were exposed to 3 freeze-thaw cycles before IL-1ß concentration was determined by radioimmunoassay (17). Antibody to IL-1ß was purchased from Cistron Biotechnology (Pine Brook, NJ). Recombinant IL-1ß was purchased from Genzyme (Cambridge, MA). [125I]IL-1ß was purchased from DuPont NEN.
Interleukin 2 and prostaglandin E2 production
PBMCs, at 1 x 106 cells/well (1 mL) in complete RPMI with 9% autologous plasma, were cultured in 24-well flat-bottom plates (Becton Dickinson Labware) in the presence or absence of ConA or PHA at 50 mg/L for 48 h. Cell-free supernates were collected and stored at -70°C for later analysis of interleukin 2 (IL-2) and prostaglandin E2 (PGE2). IL-2 activity was measured by using the bioassay method described by Gillis et al (18). Briefly, the samples, in graded dilutions, were cultured with cytotoxic T lymphocyte line 2 (CTLL-2) cells for 24 h. Cultures were pulsed by adding 18.5 µBq [3H]thymidine during the last 6 h before they were harvested. Recombinant IL-2 (Genzyme) was used as the standard. One unit per milliliter is defined as the amount of recombinant IL-2 that causes a half-maximal incorporation of [3H]thymidine into 5 x 103 CTLL-2 cells. PGE2 was measured by radioimmunoassay as described by McCosh et al (19). The PGE2 antibody was provided by J Dupont of Florida State University, Tallahassee, and M Mathias of the Agricultural Research Service in Washington, DC. The antibody has a cross-reactivity of 19% with PGE1; its specificity and cross-reactivity were described previously (20).
Delayed-type hypersensitivity skin response
Delayed-type hypersensitivity (DTH) was assessed with a Multi-Test CMI (Merieux Institute Inc, Miami), a single-use, disposable applicator of acrylic resin with 8 heads loaded with a glycerin control and the following 7 recall antigens: tetanus toxoid, diphtheria toxoid, streptococcus (group C), Mycobacterium tuberculosis, Candida albicans, Trichophyton mentagrophytes, and Proteus mirabilis, as previously described. The diameter of positive reactions was measured 24 and 48 h after administration of the test. The detailed procedure was described previously (21, 22).
Hematology and lymphocyte subsets
Whole blood was examined with a Baker 9000 Hematology Analyzer for red blood cell and white blood cell counts; a blood smear was used to estimate white blood cell differential counts by microscopy. Lymphocyte subsets were determined by flow cytometry as described previously (21). Briefly, 5 x 105 PBMCs were stained for 30 min on ice with fluorescein- or phycoerythrin-conjugated monoclonal antibodies (Becton Dickinson, San Jose, CA) to total T cells (Leu 4, Anti-CD3), T-helper cells (Leu 3, Anti-CD4), T-cytotoxic/suppressor cells (Leu 2, Anti-CD8), and B cells (Leu 12, Anti-CD19). Cytometric analyses were conducted by using a flow cytometer (FACScan, Becton Dickinson).
Membrane fluidity
Membrane fluidity was measured by using 1,6-diphenyl-1,3,5-hexatriene (DPH; Sigma) as a fluorescence polarization probe (23, 24). Isolated PBMCs were washed twice with phosphate-buffered saline and 8 x 106 cells were incubated with 4 µmol DPH/L for 45 min at 37°C. Fluorescence intensity was measured by using a Beckman LS-5 spectrofluorometer equipped with a thermostat-controlled cell holder and a polarization accessory. The steady state fluorescence polarization was measured at 37°C by exciting the cells at 360 nm and recording the emission at 430 nm at 4 combinations of polarizer position. The fluorescence polarization was calculated by using the following equation:
|
| (1) |
where P is polarization, I is the measured fluorescence intensity, the first and second subscripts represent the plane of polarization for the excitation and emission beams, respectively, and v and h denote the vertical and horizontal positions, respectively. The fluorescence polarization is inversely related to the fluidity of the membrane.
Statistical analysis
Sample size was calculated on the basis of our previous supplementation studies in which subjects with similar characteristics were evaluated by using the same immunologic methods as those used in the current study (21, 25). On this basis, a sample size of 12 is needed to detect a difference
30% at P = 0.05 with 80% power.
Data were analyzed by using the SYSTAT statistical package (SYSTAT 7.0, 1997; SYSTAT, Inc, Evanston, IL). Data within each group were analyzed by paired Student's t test or the nonparametric, paired Wilcoxon signed ranks test when the data were not normally distributed. The comparison of change between groups was conducted by using Student's t test or Kruskal-Wallis one-way analysis of variance when the distribution was not normal.
| RESULTS |
|---|
|
|
|---|
|
-linolenic acid,
-linolenic acid, stearidonic acid, and dihomo-
-linolenic acid (20:3n-6) compared with baseline. When the changes over 2 mo of supplementation were compared between the BCSO and placebo groups, a significantly larger increase in the concentrations of
-linolenic acid, dihomo-
-linolenic acid, and stearidonic acid, but an increase only marginally larger (P = 0.08) in
-linolenic acid, was observed in the BCSO group.
|
|
|
|
|
|
| DISCUSSION |
|---|
|
|
|---|
-linolenic and
-linolenic acids, on the immune response of healthy elderly subjects.
DTH skin tests have been widely used as an in vivo assay to determine cell-mediated immune function. Several investigators have shown that a decrease in DTH is associated with increased morbidity and mortality (32, 33). In this study, BCSO significantly increased the total diameter of induration after 24 h and response to specific antigens (tetanus toxoid and T. mentagrophytes), when compared with presupplementation measurements. This increase, however, was significantly different from the change in the placebo group only in response to tetanus toxoid. Few studies have evaluated the effect on DTH of oils containing
-linolenic acid. Nerad et al (34) showed that consumption of 2 g
-linolenic acid/d, provided through borage oil for 12 wk, increased the cumulative score (total diameter of induration) in healthy young volunteers. The dose of
-linolenic acid and the duration of supplementation in their study were larger (2 g
-linolenic acid/d for 3 mo) than that in the current study (0.675 g
-linolenic acid/d for 2 mo). In an animal study (35), however, the intravenous injection of 0.05 or 0.5 mL 10% dihomo-
-linolenic acid (immediate metabolic product of
-linolenic acid) emulsion suppressed DTH in mice. The suppressive effect observed in that study could have been due to the much higher amount of dihomo-
-linolenic acid administered. High fatty acid intakes, regardless of the degree of unsaturation of the fatty acids, have been shown to suppress immune response (36).
In this study, BCSO supplementation also caused a modest, but significant, increase in proliferative response of PBMCs to the T cell mitogen PHA. No significant effect was observed on the production of the proinflammatory cytokine IL-1ß or the T cell growth factor IL-2.
Devi and Das (37) examined the in vitro effect of several PUFAs (linoleic acid,
-linolenic acid,
-linolenic acid, eicosapentaenoic acid, and docosahexaenoic acid) on human lymphocytes and on the leukemic cell line Molt-2; they found that all PUFAs dose-dependently inhibited lymphocyte proliferation, with
-linolenic acid being the most inhibitory. In addition, they noted that all PUFAs reduced IL-2 production in human lymphocytes but elevated IL-2 production in Molt-2 cells (37). Madhavi et al (38) confirmed in vitro inhibition of lymphocyte proliferation by PUFAs, including
-linolenic acid at 40 mg/L. In contrast, Kelly and Parker (39) reported that linoleic acid,
-linolenic acid, dihomo-
-linolenic acid, and arachidonic acid stimulated at low concentrations (0.11.0 mg/L), but inhibited at high concentrations (>10 mg/L), the proliferative response of human lymphocytes to mitogens. The differences between the in vitro and in vivo studies as well as within the in vitro studies themselves could be due to the differences in the final concentration of
-linolenic acid to which the immune cells were exposed.
Dietary supplementation with
-linolenic acid has been shown to suppress lymphocyte proliferation but increase IL-2 production by PBMCs from healthy young subjects (34), and to enhance the ConA-induced proliferative response of rat splenocytes (40). In this study, the moderate enhancement of cell-mediated immune function in the BCSO group was not accompanied by a change in production of IL-1 or IL-2, both of which are involved in the regulation of T cell activation. Nor was there any change in the lymphocyte subpopulations. This agrees with the study reported by Harbige et al (40) in which oral
-linolenic acid administration to Lewis rats enhanced splenocyte proliferation but had no effect on the proportion of splenic CD4+ and CD8+ lymphocytes. A more recent study, however, showed that Brown-Norway rats fed a diet containing evening primrose oil (6.5%
-linolenic acid) had a higher percentage of CD4+ T cells than did those fed diets containing safflower oil or pine seed oil (neither of which has a detectable amount of
-linolenic acid (41). These inconsistent results may be due to differences in animal models, human subject characteristics (such as age and sex), source and dose of
-linolenic acid, or the route of administration used in these studies.
Because dietary lipids can modify membrane fatty acid composition, which can in turn influence the function of the immune cells, we hypothesized that a BCSO-induced change in membrane fluidity is a possible mechanism of its effect. There was, however, no effect of BCSO on membrane fluidity. Still, this does not rule out the possibility that BCSO-induced changes in specific lipid domains associated with important membrane proteins might have caused the observed effects.
Another mechanism through which BCSO can enhance cell-mediated immunity is through reduction of PGE2 production.
-Linolenic acid can be readily converted to dihomo-
-linolenic acid.
-Linolenic acid supplementation increases dihomo-
-linolenic acid concentrations in tissues but causes little or no change in arachidonic acid concentrations (4245). In agreement with previous studies (13, 44, 4648), we found that after dietary BCSO supplementation, plasma
-linolenic acid and dihomo-
-linolenic acid concentrations were higher, but the arachidonic acid concentration did not change (possibly because of poor
5 desaturase activity), resulting in an increased ratio of dihomo-
-linolenic to arachidonic acids. Increased dihomo-
-linolenic acid, either formed from
-linolenic acid or directly provided in food, has been shown to increase PGE1 (46, 49, 50) and suppress PGE2 and leukotriene B4 production (13, 48, 50), a consequence of the competition between dihomo-
-linolenic acid and arachidonic acid for prostaglandin endoperoxide synthase (cyclooxygenase) and arachidonate 5-lipoxygenase. PGE2 is a well-known suppressor of T cell function (51). Leukotriene B4 has diverse inflammatory activity and has also been reported to down-regulate lymphocyte proliferation (52). In this study, a significant decrease in PGE2 production was observed after consumption of BCSO. PGE2 was measured by radioimmunoassay and the antibody used in the assay had 19% cross-reactivity with PGE1. Because of sample limitations, we were unable to separate PGE1 and PGE2 before analysis by radioimmunoassay. However, as reported previously (46, 49, 50), it is reasonable to assume that increased dihomo-
-linolenic acid would lead to increased PGE1 synthesis. Thus, PGE1 may have contributed to a portion of the PGE2 reported in the subjects consuming BCSO; ie, the data presented in Table 5
might be an overestimation of PGE2 concentrations in the BCSO group. Thus, the moderate enhancement of immune response observed after
-linolenic acid supplementation can, at least in part, be attributed to the decreased PGE2 production.
We used BCSO as a source of
-linolenic acid in this study. In addition to n-6 PUFAs, BCSO contains more
-linolenic acid and stearidonic acid (not detectable in soybean oil) than does soybean oil. The plasma fatty acid profiles reflected the increased intake of these 2 fatty acids. Our previous study showed no significant effect of dietary supplementation with 3.5% and 5.3%
-linolenic acid for 28 wk on lymphocyte proliferation, IL-2, and PGE2 production in nonhuman primates (3). The effect of stearidonic acid on immune function is not known. Guichardant et al (53) observed that stearidonic acid inhibited the synthesis of arachidonate 5-lipoxygenase product of arachidonic acid, leukotriene B4, and 5-hydroxyeicosatetraenoic acid in an in vitro study using human leukocytes. In addition, preincubation with stearidonic acid was reported to reduce the synthesis of hydroxyheptadecatrienoic acid, a prostaglandin endoperoxide synthase product, from endogenous arachidonic acid in human platelets. This suggests that stearidonic acid may contribute to the BCSO-induced reduction in PGE2 production. Plasma concentrations of eicosapentaenoic acid and docosahexaenoic acid were unchanged by BCSO consumption despite increased precursor fatty acids
-linolenic acid and stearidonic acid, indicating an inefficient in vivo conversion process.
In conclusion, BCSO consumption does not adversely affect the immune response of healthy elderly subjects and may have a moderate immunoenhancing effect that is, in part, due to its reduction of PGE2 production.
| ACKNOWLEDGMENTS |
|---|
| REFERENCES |
|---|
|
|
|---|
-linolenic and linoleic acids. Determination of the optimal omega 3-to-omega 6 ratio. Proc Natl Acad Sci U S A 1993;90:103459.
-linolenic acid,
-linolenic acid, stearidonic acid, EPA, etc. JPEN J Parenter Enteral Nutr 1988;12(suppl):111S23S.
-linolenate desaturation by rat liver microsomes. Biochem Biophys Res Commun 1989;163:34855.[Medline]
in unextracted plasma, serum and myocardium. Prostaglandins 1976;12:47186.[Medline]
-linolenoyl-glycerol into mice and its effects on delayed-type hypersensitivity. Lipids 1993;28:8736.[Medline]
-linolenic acid. Br J Nutr 1995;74:70115.[Medline]
-linolenic acid and its positional isomer pinolenic acid on immune parameters of Brown-Norway rats. Prostaglandins Leukot Essent Fatty Acids 1996;55:2239.[Medline]
-linolenic acid on plasma n-6 fatty acids and prostaglandin biosynthesis after burn and endotoxin injury in rats. Crit Care Med 1993;21:17409.[Medline]
-linolenic acid alters fatty acid content and eicosanoid production in healthy humans. J Nutr 1997;127:143544.
-linolenic acid enhances mouse macrophage-derived prostaglandin E1 which inhibits vascular smooth muscle cell proliferation. J Nutr 1997;127:176571.This article has been cited by other articles:
![]() |
D. Wu, S. N. Han, M. Meydani, and S. N. Meydani Effect of concomitant consumption of fish oil and vitamin e on T cell mediated function in the elderly: a randomized double-blind trial. J. Am. Coll. Nutr., August 1, 2006; 25(4): 300 - 306. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kaminogawa and M. Nanno Modulation of Immune Functions by Foods Evid. Based Complement. Altern. Med., December 1, 2004; 1(3): 241 - 250. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. I. Block and M. N. Mead Immune System Effects of Echinacea, Ginseng, and Astragalus: A Review Integr Cancer Ther, September 1, 2003; 2(3): 247 - 267. [Abstract] [PDF] |
||||
![]() |
K. J. Claycombe, D. Wu, M. Nikolova-Karakashian, H. Palmer, A. Beharka, K. E. Paulson, and S. N. Meydani Ceramide Mediates Age-associated Increase in Macrophage Cyclooxygenase-2 Expression J. Biol. Chem., August 16, 2002; 277(34): 30784 - 30791. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Thies, G. Nebe-von-Caron, J. R. Powell, P. Yaqoob, E. A. Newsholme, and P. C. Calder Dietary Supplementation with {{gamma}}-Linolenic Acid or Fish Oil Decreases T Lymphocyte Proliferation in Healthy Older Humans J. Nutr., July 1, 2001; 131(7): 1918 - 1927. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Boelsma, H. F. Hendriks, and L. Roza Nutritional skin care: health effects of micronutrients and fatty acids Am. J. Clinical Nutrition, May 1, 2001; 73(5): 853 - 864. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Thies, G. Nebe-von-Caron, J. R Powell, P. Yaqoob, E. A Newsholme, and P. C Calder Dietary supplementation with eicosapentaenoic acid, but not with other long-chain n-3 or n-6 polyunsaturated fatty acids, decreases natural killer cell activity in healthy subjects aged >55 y Am. J. Clinical Nutrition, March 1, 2001; 73(3): 539 - 548. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. C. King, R. E. Black, M. P. Doyle, K. L. Fritsche, B. H. Halbrook, O. A. Levander, S. N. Meydani, W. A. Walker, and C. E. Woteki Foodborne Illnesses and Nutritional Status: A Statement from an American Society for Nutritional Sciences Working Group J. Nutr., October 1, 2000; 130(10): 2613 - 2617. [Full Text] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |